Givaudan reports 8.60 percent growth while Givaudan stock costs EUR 3,980.50

Published on 10/13/2026 at 10:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nine-month sales grew 5.20 percent to CHF 5.89 billion, above 3.90 percent consensus. Givaudan stock costs EUR 3,980.50 on October 13, 2026.

Givaudan reported third-quarter like-for-like sales growth of 8.60 percent on October 13, 2026, above 4.70 percent consensus.
Nine-month sales reached CHF 5.89 billion, up 5.20 percent like-for-like, while Fragrance & Beauty grew 8.80 percent.
Givaudan stock was trading at EUR 3,980.50 at Lang & Schwarz on October 13, 2026 at 10:04 a.m. CEST.
Barclays upgraded Givaudan to Overweight on October 5, 2026 and raised its target from CHF 3,450.00 to CHF 3,850.00.

Givaudan CH0010645932 fotorealistisches Parfumeur-Atelier mit Reagenzgläsern, getrockneten Blüten und warmem goldenem Nachmittagslicht, Illustration mit AI erstellt.

Givaudan (CH0010645932) reported third-quarter like-for-like sales growth of 8.60 percent on October 13, 2026, while its stock was trading at EUR 3,980.50 at Lang & Schwarz at 10:04 a.m. CEST. MarketScreener reported that the result exceeded the company-compiled 4.70 percent consensus.

Sales accelerate beyond consensus

MarketScreener reported nine-month sales of CHF 5.89 billion, up 5.20 percent on a like-for-like basis and 2.60 percent in Swiss francs. That compares with 3.90 percent consensus growth and gives the current result a clear operating benchmark.

Fragrance & Beauty sales rose 8.80 percent like-for-like to CHF 3.15 billion in the first nine months of 2026, while Taste & Wellbeing increased 1.50 percent like-for-like to CHF 2.74 billion. The split matters because fragrance supplied the sharper acceleration, while the taste division remains the slower contributor.

What drove the 8.60 percent result

In the third quarter of 2026, Fragrance & Beauty grew 13.50 percent like-for-like, compared with 3.50 percent for Taste & Wellbeing. Onvista reported that Taste & Wellbeing had improved from 0.50 percent organic growth in the first half of 2026, while Fragrance & Beauty remained the main growth driver.

Givaudan maintained its medium-term target of 4.00 to 6.00 percent average like-for-like sales growth and adjusted free cash flow above 12.00 percent of sales through its 2030 strategy cycle. The current nine-month growth rate is therefore above the target band, although the company still has to convert the third-quarter pace into durable full-year performance.

Analysts raise the valuation bar

Barclays upgraded Givaudan from Equal Weight to Overweight on October 5, 2026 and raised its price target from CHF 3,450.00 to CHF 3,850.00. Markets Insider attributed the change to a more attractive risk and reward profile and easing concerns about fine fragrance market share.

Three dated milestones

On July 24, 2026, Givaudan's first-half results included CHF 3.80 billion of revenue, CHF 475.00 million of net income and adjusted earnings per share of CHF 51.46, according to Simply Wall St. Barclays then raised its target to CHF 3,850.00 on October 5, 2026, before the October 13, 2026 nine-month sales update.

Next dates for Givaudan

Simply Wall St lists January 27, 2027 for fiscal year 2026 results and March 24, 2027 for Givaudan's annual general meeting.

Current price and Swiss listing

Givaudan was trading at EUR 3,980.50 at Lang & Schwarz on October 13, 2026 at 10:04 a.m. CEST. The SIX listing was last at CHF 3,723.00 on October 13, 2026 at 9:53 a.m. CEST, against a 52-week range of CHF 2,566.00 to CHF 3,746.00 and a market capitalization of CHF 34.4 billion.

Givaudan's next quantified test is the conversion of the 13.50 percent third-quarter Fragrance & Beauty growth into sustained group performance through the January results date. The further course of trading is shown by the continuously updated real-time quote of Givaudan stock.